These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 33067414)
61. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721 [TBL] [Abstract][Full Text] [Related]
62. The Role of Early Intervention in High-Risk Smoldering Myeloma. Joseph NS; Dhodapkar MV; Lonial S Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141 [TBL] [Abstract][Full Text] [Related]
63. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. Mohyuddin GR; Chakraborty R; Cliff ERS; Derman BA EClinicalMedicine; 2023 Nov; 65():102272. PubMed ID: 38046471 [TBL] [Abstract][Full Text] [Related]
64. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Rosiñol L; Carrió A; Bladé J; Queralt R; Aymerich M; Cibeira MT; Esteve J; Rozman M; Campo E; Montserrat E Br J Haematol; 2005 Sep; 130(5):729-32. PubMed ID: 16115129 [TBL] [Abstract][Full Text] [Related]
65. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Golombick T; Diamond TH; Manoharan A; Ramakrishna R Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809 [TBL] [Abstract][Full Text] [Related]
66. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan]. Takamatsu Y; Muta T Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559 [TBL] [Abstract][Full Text] [Related]
67. Smoldering Multiple Myeloma: To Treat or Not to Treat. Kapoor P; Rajkumar SV Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862 [TBL] [Abstract][Full Text] [Related]
69. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818 [TBL] [Abstract][Full Text] [Related]
70. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Gkotzamanidou M; Christoulas D; Souliotis VL; Papatheodorou A; Dimopoulos MA; Terpos E Med Sci Monit; 2013 Dec; 19():1188-94. PubMed ID: 24355943 [TBL] [Abstract][Full Text] [Related]
71. Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. Markus E; Trestman S; Cohen Y; Angel Y; Sofer Y; Mittelman M; Avivi I; Stern N; Izkhakov E BMC Cancer; 2020 May; 20(1):489. PubMed ID: 32473631 [TBL] [Abstract][Full Text] [Related]
72. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M; Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922 [TBL] [Abstract][Full Text] [Related]
73. Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Özkurt ZN; Sucak GT; Akı ŞZ; Yağcı M; Haznedar R Cancer Invest; 2017 Mar; 35(3):195-201. PubMed ID: 28112977 [TBL] [Abstract][Full Text] [Related]
74. Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma. Jamet B; Bailly C; Carlier T; Touzeau C; Michaud AV; Bourgeois M; Moreau P; Bodet-Milin C; Kraeber-Bodere F Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092901 [TBL] [Abstract][Full Text] [Related]
75. Smoldering multiple myeloma: natural history and recognition of an evolving type. Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966 [TBL] [Abstract][Full Text] [Related]
76. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Tschautscher M; Rajkumar V; Dispenzieri A; Lacy M; Gertz M; Buadi F; Dingli D; Hwa L; Fonder A; Hobbs M; Hayman S; Zeldenrust S; Lust J; Russell S; Leung N; Kapoor P; Go R; Lin Y; Gonsalves W; Kourelis T; Warsame R; Kyle R; Kumar S Am J Hematol; 2018 Oct; 93(10):1207-1210. PubMed ID: 30016549 [TBL] [Abstract][Full Text] [Related]
78. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149 [TBL] [Abstract][Full Text] [Related]
79. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449 [No Abstract] [Full Text] [Related]
80. State of the science in smoldering myeloma: Should we be treating in the clinic? Hill E; Dew A; Kazandjian D Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]